Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)

Trial Profile

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Lurbinectedin (Primary) ; Doxorubicin liposomal; Topotecan
  • Indications Ovarian cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CORAIL
  • Sponsors PharmaMar
  • Most Recent Events

    • 08 Nov 2017 This trial has been completed in Czech Republic.
    • 04 Nov 2017 According to a PharmaMar media release, data are expected in 2018.
    • 17 May 2017 Data from this trial are expected to be available later this year according to a Specialised Therapeutics Asia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top